ストックスクリーナーアプリを入手
5.88
3.61%
-0.2201
プレマーケット:
5.98
0.10
+1.70%
前日終値:
$6.1001
開ける：
$6.31
24時間の取引高:
4,331
Relative Volume:
0.29
時価総額：
$3.13M
収益：
-
当期純損益:
$-13.03M
株価収益率:
-0.0474
EPS:
-124.0371
ネットキャッシュフロー:
$-6.53M
1週間 パフォーマンス:
+6.72%
1か月 パフォーマンス:
+33.33%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.5001
$6.31
1週間の範囲:
$5.29
$6.55
52週間の値動き範囲:
$4.3201
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Compare DCOY vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
5.88 | 3.25M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-23 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-04-27 | 開始されました | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc (DCOY) 最新ニュース
Decoy Therapeutics: David Arthur Completing His Service on the Board >DCOY - Moomoo
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London - PR Newswire
[RW] Decoy Therapeutics Inc. SEC Filing - Stock Titan
DCOY | Decoy Therapeutics Inc. Common Executive Compensation - Quiver Quantitative
Decoy Therapeutics (DCOY) details 2026 director, pay and auditor votes - Stock Titan
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Offset Investor ConcernsSpecial Dividend Alert - newsline.com
Decoy Therapeutics nominates Patricia Gauthier to board - Investing.com UK
Decoy Therapeutics nominates Patricia Gauthier to board By Investing.com - Investing.com South Africa
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PR Newswire
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker - Proactive Investors
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Ca - GuruFocus
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics - Proactive Investors
hVIVO to support Decoy Therapeutics respiratory antiviral development - Vox Markets
hVIVO signs consultancy deal with Decoy Therapeutics By Investing.com - Investing.com Canada
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic - Financial Times
HVIVO plc Signs Consultancy Contract With Decoy Therapeutics - marketscreener.com
Decoy Therapeutics (DCOY) Surges 10.75%: Is Momentum Building for the Biotech Stock?ATR Stop - The Legal Advocate
Decoy Therapeutics names MIT professor as advisory board chair - Investing.com
Decoy Therapeutics names MIT professor as advisory board chair By Investing.com - Investing.com Canada
Decoy Therapeutics Inc. Announces Appointment of Brad L. Pentelute as Chair of Scientific Advisory Board - marketscreener.com
Decoy Therapeutics (DCOY) Surges 13.5%: Testing Key Resistance at $7.67Modified Schiff - The Legal Advocate
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DCOY Sets May 22 Vote, Puts Focus Back on Thinly Traded Stock - Bez Kabli
hVIVO to host capital markets day as it pitches broader clinical development role - Yahoo Finance UK
Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date - TipRanks
Decoy Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Australia
Number of shareholders of Decoy Therapeutics Inc. – NASDAQ:DCOY - TradingView
Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com Nigeria
Certain Restricted Stock Units of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
Certain Stock Options of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
1,051,782 Common Stock of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
Decoy Therapeutics Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Decoy Therapeutics: Q1 Earnings Snapshot - KTEN
Decoy Therapeutics Inc. 1Q 2026: Net loss $(2.22M), EPS $(4.18) — 10-Q Summary - TradingView
Decoy Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DCOY Q1'26 Earnings: EPS estimate is (4.12) USD - TradingView
Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - BioSpace
Decoy Therapeutics (DCOY) Proxy Filing Summary - Quartr
Decoy Therapeutics Inc (FRA:FP11) Stock PDF (Updated: 2026/04/27) - GuruFocus
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston - Intellectia AI
Decoy Therapeutics Inc (FRA:FP11) Stock Earnings Transcripts - GuruFocus
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Decoy Therapeutics Inc (DCOY) 財務データ
収益
当期純利益
現金流量
EPS
Decoy Therapeutics Inc (DCOY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):